Urinary N-telopeptide is a rapid predictor of response to and palliative benefit from bisphosphonate therapy in patients with metastatic breast cancer

Supportive Cancer Therapy

Volumn 4, Issue 4, 2007, Pages 182-187

  Simmons, Christine ^a   Broom, Reuben J ^a   Cole, David E C ^b,c   Dranitsaris, George ^a   Clemons, Mark ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Pamidronate; Quality of life; Skeletal related events; Zoledronic acid

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLLAGEN; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL TRIAL; HUMAN; OSTEOLYSIS; PAIN ASSESSMENT; REVIEW;

EID: 35348930083     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2007.n.013     Document Type: Review

References (28)

1. Gainford MC, Dranitsaris G, Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005; 330:769-773.
2. Palma MM, Body JJ. Usefulness of bone formation markers in breast cancer. Int J Biol Markers 2005; 20:146-155.
3. Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancel. BMJ 2003; 327:469-475.
4. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23:8580-8587.
5. Rosen CJ, Tenenhouse A. Biochemical markers of bone turnover. A look at laboratory tests that reflect bone status. Postgrad Med 1998; 104:101-114.
6. Hanson DA, Eyre DR. Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem 1996; 271:26508-26516.
7. Hanson DA, Weis MA, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7:1251-1258.
8. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88(12 suppl):2919-2926.
9. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655-1664.
10. Blatt JM, Allen MP, Baddam S, et al. A miniaturized, self-contained, single-use, disposable assay device for the quantitative determination of the bone resorption marker, NTx, in urine. Clin Chem 1998; 44:2051-2052.
11. Ju HS, Leung S, Brown B, et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem 1997; 43:1570-1576.
12. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001; 47:1443-1450.
13. Myers R, Minuk T, Johnston M, et al. Diagnostic imaging in breast cancer: recommendatons report. Cancer Care Ontario Practice Guidelines Web site. Available at: http://cancercare.on.ca./pdf/pebcdibrf.pdf. Accessed July 9, 2007.
14. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20:850-856.
15. Vinholes J, Coleman R, Lacombe D, et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer 1999; 80:221-228.
16. Coleman R, Major P, Lipton A, et al. Predictive value of bone resorptive and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-4935.
17. Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 2003; 89:2031-2037.
18. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335:1785-1791.
19. Theriault R, Lipton A, Hortobagyi G, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17:846-854.
20. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90:1133-1137.
21. Lipton A, Demers L, Curly E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998; 34:2021-2026.
22. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind comparative trial. Cancer J 2001; 7:377-387.
23. Coleman RE, Purohit OP, Black C, et al. Double-blind, randomized, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999; 10:311-316.
24. Rosen L, Gordon D, Kaminski M, et al. Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003; 98:1735-1744.
25. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1-18.
26. Vinholes JJ, Purohit OP, Abbey ME, et al. Relatioships between biochemical and symptomatic response in a double-blind randomized trial of pamidronate for metastatic disease. Ann Oncol 1997; 8:1243-1250.
27. Clemons M, Dranitsatis G, Ooi W, et al. A phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event or progressive bone metastases despite first line bisphosphonate therapy. J Clin Oncol 2006; 24:4895-4900.
28. Clemons M, Dranitsaris G, Ooi WS, et al. Oral ibandronate provides significant palliative benefit in metastatic breast caner patients who have experienced bony progression or a skeletal related event (SRE) despite first-line bisphosphonate therapy. Presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract #3147.